MCID: MNT001
MIFTS: 55

Mantle Cell Lymphoma malady

Rare diseases, Cancer diseases, Blood diseases, Immune diseases categories

Aliases & Classifications for Mantle Cell Lymphoma

About this section
Sources:
30LifeMap Discovery®, 8Disease Ontology, 42NIH Rare Diseases, 10DISEASES, 44Novoseek, 48Orphanet, 22GTR, 61UMLS, 34MESH via Orphanet, 26ICD10 via Orphanet, 25ICD10
See all sources

Aliases & Descriptions for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma 30 8 42 10 48
Mantle Zone Lymphoma 42 48
Lymphoma Mantle-Cell 44 22
Lcm 42 48
Mcl 42 48
 
Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse 61
Malignant Lymphoma - Lymphocytic, Intermediate Differentiation 61
Lymphocytic Choriomeningitis 61
Lymphoma, Mantle Cell 42


Classifications:



Characteristics (Orphanet epidemiological data):

48
mantle cell lymphoma:
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (United States),1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult


External Ids:

Disease Ontology8 DOID:0050746
Orphanet48 52416
MESH via Orphanet34 D020522
ICD10 via Orphanet26 C83.1
ICD1025 C83.1

Summaries for Mantle Cell Lymphoma

About this section
NIH Rare Diseases:42 Mantle cell lymphoma (mcl) belongs to a group of diseases known as  non-hodgkin’s lymphomas (nhl), which are cancers that affect the the lymphatic system (part of the immune system). mcl accounts for 6% of all non-hodgkin lymphomas and is mostly found in males during their early 60s. lymphocytes, which are white blood cells that make up the lymphatic system. there are two main types: b-lymphocytes (b-cells) and t-lymphocytes (t-cells). mantel cell lymphoma is a b-cell lymphoma that develops from cancerous b-cells within a region of the lymph node known as the mantle zone. although mantle cell lymphomas are slow-growing cancers, at the time of diagnosis, they are usually widespread in the lymph nodes and require intensive treatment because they can become lethal within a short period of time. last updated: 7/20/2011

MalaCards based summary: Mantle Cell Lymphoma, also known as mantle zone lymphoma, is related to chronic lymphocytic leukemia and macroglobulinemia, and has symptoms including lymphadenopathy, hematological neoplasm and splenomegaly. An important gene associated with Mantle Cell Lymphoma is CCND1 (cyclin D1), and among its related pathways are TP53 network and FOXM1 transcription factor network. The compounds okadaic acid and tyrosine have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and lymph node, and related mouse phenotypes are tumorigenesis and hematopoietic system.

Disease Ontology:8 A b-cell lymphocytic neoplasm due to cd5 positive antigen-naive pregerminal center b-cell within the mantle zone that surrounds normal germinal center follicles.

Wikipedia:64 Mantle cell lymphoma (MCL) is a type of non-Hodgkin\'s lymphoma (NHL), comprising about 6% of NHL cases.... more...

Related Diseases for Mantle Cell Lymphoma

About this section

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 102)
idRelated DiseaseScoreTop Affiliating Genes
1chronic lymphocytic leukemia31.3IGH, CD5, CCND1, IGHM, ATM
2macroglobulinemia31.3CD5
3hodgkin lymphoma31.2IGHM, CCND2, IGH, ATM
4multiple myeloma31.2CKS1B, CCND1, CCND2
5b-cell lymphomas31.1IGHM, CD5, CCND1, IGH, ATM, CCND2
6myeloma31.1IGH, IGHM, CCND2, CCND1
7malt lymphoma31.0CD5, CCND1, IGHM, IGH
8follicular lymphoma31.0CD5, CCND1, IGHM, IGH
9leukemia31.0CCND1, IGH, PRAME, ATM, CD5, CD52
10prolymphocytic leukemia30.9CD5, CCND1, ATM
11waldenstrom macroglobulinemia30.8IGHM, IGH, CCND1
12acute leukemia30.3ATM, IGH, PRAME
13adenoma30.2CCND2, CCND1, ATM, CKS1B
14diffuse large b-cell lymphoma10.7
15marginal zone b-cell lymphoma10.5
16prostatitis10.5
17splenomegaly10.5
18hematopoietic stem cell transplantation10.5
19cryoglobulinemia10.4CD5
20glomerulonephritis10.4
21splenic marginal zone lymphoma10.4
22composite lymphoma10.4
23endotheliitis10.4
24cryoglobulinemia, familial mixed10.3IGHM, CD5
25gastrointestinal stromal tumor10.3
26ataxia-telangiectasia10.3
27peripheral t-cell lymphoma10.3
28thrombocytopenia10.3
29membranoproliferative glomerulonephritis10.3
30leukostasis10.3
31adenocarcinoma10.3
32interstitial nephritis10.3
33pancreatitis10.3
34ataxia10.3
35nephritis10.3
36glomus tumor10.3
37wells syndrome10.3
38squamous cell carcinoma, head and neck10.3IGH, IGHM, CD5, CCND1
39malignant glioma10.2CCND2, CCND1, SOX11
40breast cancer10.2ATM, CCND1
41burkitt lymphoma10.2ATM, CCND1
42prostate cancer10.2
43retinoblastoma10.2
44renal cell carcinoma10.2
45anaplastic large cell lymphoma10.2
46focal segmental glomerulosclerosis10.2
47hepatitis10.2
48liver cirrhosis10.2
49lymphoblastic lymphoma10.2
50myasthenia gravis10.2

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:



Diseases related to mantle cell lymphoma

Symptoms for Mantle Cell Lymphoma

About this section

Symptoms:

 48 (show all 7)
  • lymphadenopathy/polyadenopathies
  • hematologic/blood/lymphatic cancer
  • splenomegaly
  • anorexia
  • bone marrow/medullar infiltration
  • weight loss/loss of appetite/break in weight curve/general health alteration
  • asthenia/fatigue/weakness

HPO human phenotypes related to Mantle Cell Lymphoma:

id Description Frequency HPO Source Accession
1 lymphadenopathy hallmark (90%) HP:0002716
2 hematological neoplasm hallmark (90%) HP:0004377
3 splenomegaly typical (50%) HP:0001744
4 weight loss typical (50%) HP:0001824
5 anorexia typical (50%) HP:0002039

Drugs & Therapeutics for Mantle Cell Lymphoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Imbruvica13 38 IBRUTINIB Pharmacyclics Approved November of 2013/Approved February 2014
FDA Label: Imbruvica
Malady that Drug Treats: mantle cell lymphoma/chronic lymphocytic leukemia
Indications and Usage:13 IMBRUVICA is a kinase inhibitor indicated for the treatment of patients with:; Mantle cell lymphoma (MCL) who have received at least one prior; therapy (1.1).; ; Accelerated approval was granted for this indication based on overall; ; response rate. Continued approval for this indication may be contingent; ; upon verification of clinical benefit in confirmatory trials.; ; Chronic lymphocytic leukemia (CLL) who have received at least one; prior therapy (1.2).; Chronic lymphocytic leukemia with 17p deletion (1.3).; Waldenström s macroglobulinemia (WM) (1.4).
DrugBank Targets:11 1. Tyrosine-protein kinase BTK
Mechanism of Action:13 
Target: Bruton's tyrosine kinase (Btk)
Action: selective inhibitor
FDA: Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine; residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a; signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK s; role in signaling through the B-cell surface receptors results in activation of pathways necessary; for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits; malignant B-cell proliferation and survival in vivo as well as cell migration and substrate; adhesion in vitro.
2
Revlimid13 38 LENALIDOMIDE Celgene Approved June 2013
FDA Label: Revlimid
Malady that Drug Treats: mantle cell lymphoma
Indications and Usage:13 REVLIMID is a thalidomide analogue indicated for the treatment of patients; with:; Multiple myeloma (MM), in combination with dexamethasone (1.1).; Transfusion-dependent anemia due to low- or intermediate-1-risk; myelodysplastic syndromes (MDS) associated with a deletion 5q; abnormality with or without additional cytogenetic abnormalities (1.2).; Mantle cell lymphoma (MCL) whose disease has relapsed or progressed; after two prior therapies, one of which included bortezomib (1.3).; Limitations of Use:; REVLIMID is not indicated and is not recommended for the treatment; of patients with chronic lymphocytic leukemia (CLL) outside of; controlled clinical trials (1.4).
DrugBank Targets:11 1. Protein cereblon; 2. Tumor necrosis factor ligand superfamily member 11; 3. Cadherin-5; 4. Prostaglandin G/H synthase 2
Mechanism of Action:13 
Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes
Action: activator/inhibitor
FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibits; proliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q); myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models; including multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increased; numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-± and IL-6) by monocytes. In multiple myeloma cells, the; combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
3
Velcade13 38 BORTEZOMIB Millennium Pharmaceuticals Approved May 2003
FDA Label: Velcade
Malady that Drug Treats: Multiple Myeloma
Indications and Usage:13 VELCADE is a proteasome inhibitor indicated for:; treatment of patients with multiple myeloma (1.1); treatment of patients with mantle cell lymphoma (1.2)
DrugBank Targets:11 1. 26S proteasome non-ATPase regulatory subunit 2; 2. 26S proteasome non-ATPase regulatory subunit 1; 3. Proteasome subunit beta type-1; 4. Proteasome subunit beta type-5; 5. Proteasome subunit beta type-2
Mechanism of Action:13 
Target: 26S proteasome
Action: reversible inhibitor of chymotrypsin-like activity
FDA: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian; cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitinproteasome; pathway plays an essential role in regulating the intracellular concentration of specific proteins,; thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted; proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic; mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of; cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models,; including multiple myeloma.

Drug clinical trials:

Search ClinicalTrials for Mantle Cell Lymphoma

Search NIH Clinical Center for Mantle Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Genetic Tests for Mantle Cell Lymphoma

About this section

Genetic tests related to Mantle Cell Lymphoma:

id Genetic test Affiliating Genes
1 Mantle Cell Lymphoma22

Anatomical Context for Mantle Cell Lymphoma

About this section

MalaCards organs/tissues related to Mantle Cell Lymphoma:

31
B cells, T cells, Lymph node, Bone, Bone marrow, Colon, Prostate, Monocytes, Skin, Endothelial, Testis, Brain, Small intestine, Kidney, Liver, Adrenal gland, Breast, Testes, Myeloid, Trachea, Appendix

Animal Models for Mantle Cell Lymphoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.5CKS1B, CCND1, PMAIP1, IGHM, ATM
2MP:00053978.5CD5, ATM, IGHM, IGL, PMAIP1, SOX11
3MP:00053878.3ATM, IGHM, IGL, PMAIP1, SOX11, CCND1

Publications for Mantle Cell Lymphoma

About this section

Articles related to Mantle Cell Lymphoma:

(show top 50)    (show all 864)
idTitleAuthorsYear
1
Ibrutinib approved for mantle cell lymphoma. (24402946)
2014
2
Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. (23730878)
2013
3
Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. (24030098)
2013
4
Molecular characterization of chromosomal band 5p15.33: a recurrent breakpoint region in mantle cell lymphoma involving the TERT-CLPTM1L locus. (23137523)
2013
5
MicroRNAs in mantle cell lymphoma. (23339447)
2013
6
Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. (23940282)
2013
7
A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma. (24107828)
2013
8
Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. (23772666)
2013
9
Current and emerging therapies in mantle cell lymphoma. (23512567)
2013
10
Mantle cell lymphoma presenting as a pelvi-ureteric junction obstruction: a case report. (23590763)
2013
11
Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. (22475365)
2012
12
Relapsed and/or Refractory Mantle Cell Lymphoma: What Role for Temsirolimus? (22550404)
2012
13
NVP-BEZ235 alone and in combination in mantle cell lymphoma: an effective therapeutic strategy. (22920938)
2012
14
FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment? (22377620)
2012
15
Scoring systems in mantle cell lymphoma: a critical point of view. (21915995)
2012
16
A retrospective study evaluating the efficacy and safety of bendamustine in the treatment of mantle cell lymphoma. (22185662)
2012
17
Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. (21067447)
2011
18
Chlorambucil in indolent mantle cell lymphoma--just another old drug for a new disease? (21271863)
2011
19
Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. (21750224)
2011
20
Prognostic relevance of clinical risk factors in mantle cell lymphoma. (21782060)
2011
21
Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma. (21509767)
2011
22
Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. (21850989)
2011
23
Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index. (21609366)
2011
24
Utility of positron emission tomography scans in mantle cell lymphoma. (21922524)
2011
25
Outcome of patients with mantle cell lymphoma is not influenced by vascular endothelial growth factor polymorphisms. (21067446)
2011
26
Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma. (21603610)
2011
27
Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. (21712452)
2011
28
Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. (20558579)
2010
29
Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells. (20647473)
2010
30
CD5-undetected by immunohistochemistry, t(11;14)(q13;q32)-positive conjunctival mantle cell lymphoma: a case report. (18572329)
2008
31
Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells. (17606765)
2007
32
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. (17136116)
2007
33
Successful treatment of focal segmental glomerulosclerosis in association with mantle cell lymphoma. (17497453)
2007
34
Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. (16461462)
2006
35
Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. (16645163)
2006
36
Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. (16155021)
2005
37
Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma. (16337199)
2005
38
Biology and therapy of mantle cell lymphoma. (16093790)
2005
39
Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. (16219581)
2005
40
Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. (16123218)
2005
41
Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. (14630827)
2004
42
Genetic and molecular genetic studies in the diagnosis of B-cell lymphomas I: mantle cell lymphoma, follicular lymphoma, and Burkitt's lymphoma. (12733111)
2003
43
PPP2R1B gene in chronic lymphocytic leukemias and mantle cell lymphomas. (11342371)
2001
44
Mantle cell lymphoma proliferates upon IL-10 in the CD40 system. (10942246)
2000
45
Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma. (11035575)
2000
46
Mantle cell lymphoma, in leukaemic phase with prominent splenomegaly. A report of eight cases with similar clinical presentation and aggressive outcome. (11193469)
2000
47
Quantitative RNA slot-blot analysis of CCND1/cyclin D1 expression in suspected mantle cell lymphoma. (9436924)
1998
48
Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. (8623927)
1996
49
Detection of bcl-1 gene rearrangement and B-cell clonality in mantle cell lymphoma using formalin-fixed, paraffin-embedded tissues. (8526214)
1995
50
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. (7595744)
1995

Variations for Mantle Cell Lymphoma

About this section

Cosmic variations for Mantle Cell Lymphoma:

6
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
122507ATMhaematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma1

Expression for genes affiliated with Mantle Cell Lymphoma

About this section
Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Pathways for genes affiliated with Mantle Cell Lymphoma

About this section

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 28)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Show member pathways
10.1PMAIP1, ATM
210.0CCND1, CKS1B
310.0CCND1, CCND2
410.0ATM, CCND2
5
Show member pathways
Development EDNRB signaling59
Development ACM2 and ACM4 activation of ERK59
Cell adhesion Integrin inside out signaling59
Development G Proteins mediated regulation MARK ERK signaling59
Signal transduction IP3 signaling59
Development Angiotensin signaling via PYK259
Development EPO induced MAPK pathway59
9.9IGH, IGHM, IGL
6
Show member pathways
Immune response Alternative complement pathway59
Immune response Lectin Induced complement pathway59
Immune response Classic complement pathway59
9.9IGHM, IGH, IGL
7
Show member pathways
Immune response T cell receptor signaling pathway59
Immune response CD28 signaling59
Immune response ICOS pathway in T helper cell59
9.9IGH, IGL, IGHM
8
Show member pathways
Immune response BCR pathway59
Fc-epsilon receptor I signaling in mast cells36
9.9IGHM, IGH, IGL
9
Show member pathways
PLK2 and PLK4 events36
Polo-like kinase signaling events in the cell cycle36
9.9CCND1, ATM, CCND2
10
Show member pathways
9.9ATM, CCND1, CCND2
11
Show member pathways
Signaling Pathways in Glioblastoma36
9.9CCND2, ATM, CCND1
12
Show member pathways
Cell cycle36
9.9CCND2, CCND1, ATM
139.9CCND2, CCND1, ATM
149.9CCND2, CCND1, ATM
159.9CCND2, PMAIP1, CCND1
169.8CD5, CCND2, IGHM
17
Show member pathways
Cell cycle ESR1 regulation of G1 S transition59
Immune response MIF JAB1 signaling59
Cell cycle Cell cycle generic schema 59
9.7CCND1, CCND2, CKS1B
18
Show member pathways
Cell cycle Role of SCF complex in cell cycle regulation59
9.7CKS1B, CCND2, CCND1
19
Show member pathways
Proteasome Degradation36
Immune response Antigen presentation by MHC class I59
9.7CCND1, PMAIP1, ATM, CKS1B
20
Show member pathways
DNA damage response36
9.7CCND1, CCND2, PMAIP1, ATM
21
Show member pathways
DNA damage response (only ATM dependent)36
Wnt Signaling Pathway and Pluripotency36
9.7ATM, CCND2, CCND1, PMAIP1
22
Show member pathways
Development IGF RI signaling
Immune response IL 4 signaling pathway59
Signal transduction AKT signaling59
9.7IGH, CCND2, CCND1, IGL
23
Show member pathways
9.6CKS1B, CCND2, CCND1, ATM
24
Show member pathways
9.6CCND2, CCND1, ATM, CKS1B
25
Show member pathways
9.6CKS1B, CCND2, ATM, CCND1
26
Show member pathways
9.5CCND2, PMAIP1, ATM, SOX11, CCND1
279.4MIR16-1, MIR29A, MIR17, MIR20A, CCND1, ATM
289.1MIR20A, CCND2, CCND1, MIR17, MIR29A, MIR16-1

Compounds for genes affiliated with Mantle Cell Lymphoma

About this section
Sources:
44Novoseek, 60Tocris Bioscience
See all sources

Compounds related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

idCompoundScoreTop Affiliating Genes
1okadaic acid44 6010.9CDK20, CCND1, ATM
2tyrosine448.8CD5, CDK20, CKS1B, CCND2, CCND1, ATM

GO Terms for genes affiliated with Mantle Cell Lymphoma

About this section

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein kinase holoenzyme complexGO:000030710.0CCND2, CCND1

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1response to X-rayGO:001016510.2CCND1, PMAIP1
2positive regulation of cyclin-dependent protein kinase activityGO:00457379.9CCND1, CCND2
3positive regulation of DNA damage response, signal transduction by p53 class mediatorGO:00435179.8PMAIP1, ATM
4cell divisionGO:00513019.4CDK20, CKS1B, CCND2, CCND1

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cyclin-dependent protein serine/threonine kinase regulator activityGO:001653810.0CKS1B, CCND1

Sources for Mantle Cell Lymphoma

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet